Nadia Rachdaoui

Dr. Nadia Rachdaoui


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NRNadia Rachdaoui
Nadia Rachdaoui
Insulin, a hormone produced by pancreatic β-cells, has a primary function of maintaining glucose homeostasis. Deficiencies in β-cell insulin secretion result in the development of type 1 and type 2 diabetes, metabolic disorders characterized by high levels of blood glucose. Type 2 diabetes mellitus (T2DM) is characterized by the presence of peripheral insulin resistance in tissues such as skeletal muscle, adipose tissue and liver and develops when β-cells fail to compensate for the peripheral insulin resistance. Insulin resistance triggers a rise in insulin demand and leads to β-cell compensation by increasing both β-cell mass and insulin secretion and leads to the development of hyperinsulinemia. In a vicious cycle, hyperinsulinemia exacerbates the metabolic dysregulations that lead to β-cell failure and the development of T2DM. Insulin and IGF-1 signaling pathways play critical roles in maintaining the differentiated phenotype of β-cells. The autocrine actions of secreted insulin on β-cells is still controversial; work by us and others has shown positive and negative actions by insulin on β-cells. We discuss findings that support the concept of an autocrine action of secreted insulin on β-cells. The hypothesis of whether, during the development of T2DM, secreted insulin initially acts as a friend and contributes to β-cell compensation and then, at a later stage, becomes a foe and contributes to β-cell decompensation will be discussed.

1 September 2013 in Endocrinology and Metabolism Clinics of North America
Verified
Journal Article
Closed access
NRNadia Rachdaoui
Nadia Rachdaoui
DSDipak K. Sarkar
Dipak K. Sarkar

1 November 2018 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
NRNadia Rachdaoui
Nadia Rachdaoui
LPLUIS POLO-PARADA
LUIS POLO-PARADA
FIFaramarz Ismail-Beigi
Faramarz Ismail-Beigi
Chronic hyperinsulinemia, in vivo, increases the resistance of peripheral tissues to insulin by desensitizing insulin signaling. Insulin, in a heterologous manner, can also cause IGF-1-resistance. The aim of the present study was to investigate whether insulin-mediated insulin and IGF-1-resistance develops in pancreatic β-cells and whether this resistance results in β-cell decompensation. Chronic exposure of rat islets or INS1-E β-cells to increasing concentrations of insulin decreased AktS473 phosphorylation in response to subsequent acute stimulation with 10 nM insulin or IGF-1. Prolonged exposure to high insulin not only inhibited AktS473 phosphorylation, but also resulted in a significant inhibition of the phosphorylation of P70S6 kinase and Erk½ phosphorylation in response to the acute stimulation by glucose, insulin or IGF-1. Decreased Akt, P70S6K and Erk½ activation were associated with decreased IRS2 tyrosine-phosphorylation and IR β-subunit abundance; neither IGFR β-subunit content nor its phosphorylation were affected. These signaling impairments were associated with decreased SERCA2 expression, perturbed plasma membrane calcium current and intracellular calcium handling, increased ER-stress markers such as eIF2αS51 phosphorylation and Bip (GRP78) expression and increased islet and β-cell apoptosis. We demonstrate that prolonged exposure to high insulin induces not only insulin resistance, but in a heterologous manner causes resistance to IGF-1 in rat islets and insulinoma cells resulting in decreased cell survival. These findings suggest the possibility that chronic exposure to hyperinsulinemia may negatively affect β-cell mass by increasing β-cell apoptosis.

1 February 2021 in Analytical Biochemistry
Verified
Journal Article
Closed access
AAAndrea Arias-Alvarado
Andrea Arias-Alvarado
MAMirjavid Aghayev
Mirjavid Aghayev
SISerguei Ilchenko
Serguei Ilchenko
NRNadia Rachdaoui
Nadia Rachdaoui
JLJosephine Lepp
Josephine Lepp
TKTakhar Kasumov
Takhar Kasumov

15 September 2020 in ACS Chemical Biology
Verified
Journal Article
Closed access
NDNatalie A. Daurio
Natalie A. Daurio
HZHaihong Zhou
Haihong Zhou
Ying ChenYing Chen
Ying Chen
PSPayal R. Sheth
Payal R. Sheth
JIJason E. Imbriglio
Jason E. Imbriglio
SPStephen F. Previs
Stephen F. Previs

1 September 2003 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
NRNadia Rachdaoui
Nadia Rachdaoui
LNLaura E Nagy
Laura E Nagy
Tumor necrosis factor-α (TNF-α) is a potent inducer of insulin resistance, and increased TNF-α expression is associated with impaired glucose disposal. Although insulin is the primary regulator of glucose transport in adipose, endothelin-1, a vasoconstrictor peptide that signals through the heterotrimeric G proteins Gαq/11, potently stimulates glucose uptake in 3T3-L1 adipocytes by a mechanism independent of phosphatidylinositol (PI) 3-kinase. Here, we report that exposure of 3T3-L1 adipocytes to TNF-α for 48 h dose-dependently decreased endothelin-1-stimulated glucose uptake and translocation of GLUT4 to the plasma membrane. TNF-α exposure had no effect on endothelin-1 receptor number at the cell surface. In contrast, TNF-α treatment reduced the quantity of Gαq/11 and proline-rich tyrosine kinase 2 (PYK2) and decreased endothelin-1-stimulated PYK2-Tyr402 tyrosine phosphorylation. Taken together, these results suggest that TNF-α-induced desensitization of endothelin-1-stimulated GLUT4 translocation and glucose uptake in 3T3-L1 adipocytes is due, at least in part, to a decreased expression of Gαq/11, leading to a suppression in tyrosine phosphorylation of PYK2.